• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 178
  • 148
  • 32
  • 18
  • 18
  • 14
  • 13
  • 11
  • 8
  • 7
  • 4
  • 3
  • 3
  • 3
  • 2
  • Tagged with
  • 492
  • 492
  • 120
  • 119
  • 77
  • 68
  • 63
  • 48
  • 47
  • 39
  • 37
  • 36
  • 36
  • 35
  • 35
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
141

AVANÇOS DO ENDOMARKETING NA CIENTIFICA FARMACÊUTICA - CIFARMA

Lira, Francisco Alves de 22 September 2009 (has links)
Made available in DSpace on 2016-08-10T10:29:35Z (GMT). No. of bitstreams: 1 Francisco Alves de Lira.pdf: 572022 bytes, checksum: 4d29248d9400f8fd7b8e7ede46eb22fd (MD5) Previous issue date: 2009-09-22 / Restructuring and qualifying internal conversation is the right way to take the internal workers to share the organization objectives and make them go towards satisfying levels, to achieve good results. The general goal of the dissertation presented was to investigate if CIFARMA, in the city of Goiania, Goiás, adopts a leadership strategy based on advertising actions referring to endomarketing programs. The applying of endomarketing philosophy was sought in the organization and is being, in fact, a tool able to elevate its competitive ability and, at the same time, improve its internal communication quality. This research is made up of a situation study, based on the application of a questionnaire applied by the general principal and people´s head manager and 19 workers from the operational base. The responses showed that the manager s position related to the endomarketing subject in pharmaceutical area, the acknowledgement of the professional values stood out and the information on all aspects connecting to the organization is a fundamental condition to having commitment, development and productivity. The workers characteristics can be known and their kinds of developed actions identified by the organization which offers a good interpersonal relationship and involvement of the workers. The information reveals that the organization achieved significant improvements in the internal communication, changing into competitive advantages, so that the developed actions in the sight of the researchers, placing the organization as serious and respectful, offering good relationship and dialogue with the superior ones. / Reestruturar e qualificar a comunicação interna é o caminho certo para levar os colaboradores internos a compartilhar os objetivos da organização e fazê-los caminhar para um nivel de satisfação desejável, para atingir bons resultados. O objetivo geral da dissertação que se apresenta foi investigar se a CIFARMA, situada em Goiânia - Goiás adota uma estratégia de gestão pautada na promoção de ações referentes a programas de endomarketing. Buscou-se avaliar se a aplicação da filosofia de endomarketing na organização está sendo, de fato, uma ferramenta capaz de elevar a sua capacidade competitiva e, ao mesmo tempo, melhorar a qualidade da comunicação interna. Esta pesquisa constitui-se de um estudo de caso, apoiando-se na aplicação de um questionário aplicado ao diretor geral e gerente de gestão de pessoas, e 19 colaboradores da base operacional. Constatouse, através das respostas, o posicionamento da gerência em relação ao assunto endomarketing no segmento farmacêutico, sendo destacado o reconhecimento da valorização dos profissionais e que a informação sobre todos os aspectos inerentes à organização é condição fundamental para que haja comprometimento, desenvolvimento e produtividade. Pôde-se conhecer o perfil dos colaboradores e identificar os tipos de ações desenvolvidas pela organização que propiciam uma boa relação interpessoal e engajamento dos colaboradores. Os dados revelaram que a organização obteve melhorias significativas na comunicação interna, transformando em vantagens competitivas, tanto que as ações desenvolvidas na visão dos pesquisados colocaram a organização como séria, respeitada, proporcionando um bom relacionamento e diálogo com os superiores.
142

Capacidades tecnológicas e transferência de tecnologia: estudo de múltiplos casos na indústria farmacêutica no Brasil e no Canadá / Technological capability and technology transfer; a case study in the pharmaceutical industry and in Canada

Takahashi, Vânia Passarini 13 December 2002 (has links)
A aquisição de conhecimentos tecnológicos tem se tornado uma prática comum para as empresas farmacêuticas desenvolverem medicamentos mais eficazes e seguros. Este trabalho tem o objetivo principal de analisar a habilidade das empresas farmacêuticas de desenvolverem suas capacidades tecnológicas através de tecnologia importada. Assim, apresenta-se um modelo conceitual de desenvolvimento de capacidades tecnológicas em empresas farmacêuticas. Este modelo analisa se os elementos críticos (capacidade de absorção, modo de transferência, natureza da tecnologia, capacidade gerencial, elementos organizacionais) podem afetar a habilidade de uma empresa de desenvolver suas capacidades tecnológicas com a tecnologia importada. Estudos de casos em sete empresas farmacêuticas no Brasil e quatro no Canadá foram realizados com a utilização do modelo conceitual. / The acquisitions of external technological knowledge have been a usual practice for the pharmaceutical firms to develop drugs more effective and safe. This work has the main objective to analyze the ability of pharmaceutical firms to develop their technological capability through imported technology. A conceptual model of development of technological capability in pharmaceutical firms is presented. This model analyze if critical elements (absorptive capacity, technology transfer modes, nature of technology, managerial capability, organizational elements) can affect the ability of firms for developing their technology capability through imported technology. Cases study in seven pharmaceutical firms in Brazil and four firms in Canada were realized.
143

Avaliação do teor de carbono orgânico total na qualidade da água: aplicação na radiofarmácia / Evaluation of total organic carbon content in the quality of the water: application in radiopharmacy

Benedetti, Stella 17 September 2012 (has links)
Radiofármacos são preparações farmacêuticas que possuem um radionuclídeo em sua composição. Cerca de 95% deles são utilizados com finalidade diagnóstica e em sua maioria são administrados por via parenteral, requerendo o uso de água purificada (AP) e para injeção (API) nos processos de produção, controle de qualidade e pesquisa de novos radiofármacos. A produção de radiofármacos no Brasil deve atender às Boas Práticas de Fabricação (BPF), RDC n. 17/2010 e RDC n. 63/2009 da ANVISA e requisitos de qualidade definidos pelas farmacopeias vigentes. Considerando que os volumes dos lotes de fabricação de radiofármacos são reduzidos, de algumas dezenas a centenas de mililitros, e a sua validade é de algumas horas a alguns dias, frequentemente tem sido utilizados sistemas purificadores de uso laboratorial para a produção de AP e API nas radiofarmácias. A determinação de carbono orgânico total (COT) é um dos requisitos a serem atendidos na avaliação da qualidade de AP e API e o seu limite é de 500 μg L-1. O objetivo deste estudo foi validar o método analítico de COT que combina reações de acidificação e de oxidação química do carbono para análise de carbono inorgânico (CI) e carbono total (CT), na análise de AP e API, avaliar o desempenho de sistemas de purificação de uso laboratorial para a produção de AP e API e comparar com a API adquirida de fornecedores externos. Utilizou-se um analisador de carbono modelo TOC-Vwp acoplado a um amostrador automático modelo ASI-V, ambos da marca Shimadzu® e controlados por software TOC Control-V e frascos de 40 mL lavados com HNO3 15%, com soluções de reagente oxidante (Na2S2O8 0,5 mol L-1) e acidificante (H3PO4 3,0 mol L-1), soluções de COT/CT (C8H5O4K) e CI (Na2CO3 e NaHCO3) nas concentrações 100-1000 μg L-1. Foram avaliados os parâmetros de validação de método: conformidade do sistema, robustez, repetibilidade, precisão intermediária, exatidão, linearidade e limites de detecção e quantificação. O desempenho de 5 sistemas de purificação foram avaliados, com amostragem de AP e API de 6 pontos (3 de AP e 3 de API) e foram analisados COT, condutividade, pH, contagem de aeróbios totais e endotoxina bacteriana (somente para API). As melhores condições de análise foram 2 mL de oxidante, 3% de acidificante, tempo de integração da curva de CT de 10 minutos e 3 minutos para CI. As curvas analíticas de CT e CI foram lineares nas faixas de concentrações analisadas, com a soma residual dos mínimos quadrados (r2) maior que 0,997. Os resultados de repetibilidade apresentaram valores entre 0,40 4,40%, a precisão intermediária por sua vez apresentou a seguinte variação, 0,65 a 4,63% e exatidão apresentou valores na faixa de 96,76-112,52%. Os limites de detecção (LD) e quantificação (LQ) foram 31,83 e 106,11 μg L-1 e 59,16 e 197,22 μg L-1, para CT e CI, respectivamente. A avaliação de desempenho dos purificadores indicam que um procedimento adequado de limpeza do reservatório de água é importante para manter a concentração de COT em cerca de 100 μg L-1. A análise de COT/CI pode ser utilizada como indicador da necessidade de manutenção do sistema purificador. Algumas API embaladas apresentaram COT acima de 500 μg L-1. O monitoramento de COT durante a avaliação de desempenho dos sistemas de uso laboratorial acoplados a reservatórios indicou que eles são equipamentos adequados para obtenção de AP e API em radiofarmácia. / Radiopharmaceuticals are pharmaceutical preparations that have one radionuclide in their composition. About 95% of them are used with diagnostic purposes and most of them are parenterally administered, requiring the use of purified water (PW) and water for injection (WFI) in the production process, quality control and research of new radiopharmaceuticals. The production of radiopharmaceuticals in Brazil must comply with Good Manufacturing Practices (GMP), RDC n. 17/2010 and RDC n. 63/2009 from ANVISA, and the requirements defined by current pharmacopoeias. Considering that the batch volumes of the radiopharmaceuticals are reduced, up to some milliliters, and the shelf lives are from hours to a few days, purification systems for laboratory use have often been used to produce PW and WFI in the radiopharmacies. The determination of Total Organic Carbon (TOC) is one of the requirements for the assessment of PW and WFI and its limit is 500 μg L-1. The aim of this study was to validate the analytical method for TOC analysis that combines acidification and chemical oxidation to quantify inorganic carbon (IC) and total carbon (TC) in the analysis of PW and WFI; to evaluate the performance of purification systems for laboratorial use to produce PW and WFI and to compare with WFI acquired from external suppliers. It was used a carbon analyzer model TOC-Vwp coupled to an autosampler model ASI-V, both from Shimadzu® controlled by TOC-V Control software and 40 mL vials washed with 15% HNO3, an oxidizing reagent (Na2S2O8 0.5 mol L-1), an acid reagent (H3PO4 3.0 mol L-1), TOC/TC (C8H5O4K) and IC (Na2CO3 and NaHCO3) solutions in the range of 0 - 1000 μg L-1. The evaluated validation parameters were system suitability, robustness, repeatability, intermediate precision, accuracy, linearity and detection and quantification limits. The performance of 5 purification systems were evaluated by sampling PW and WFI from 6 places (3 were PW and 3 WFI) and TOC, conductivity, pH, total aerobic count and bacterial endotoxin (API only) were analyzed. The best conditions of analysis were 2.0 mL oxidizing reagent, 3% acid reagent, 10 minutes integration curve time for TC and 3 minutes for IC. The TC and IC analytical curves were linear in the evaluated range, with residual sum of minimum squares (r2) greater than 0.997. The results of repeatability were from 0.40 to 4.40%, intermediate precision were from 0.65 to 4.63%, and accuracy were in the range of 96.76 to 112.52%. The detection limit (DL) and quantification limit (QL) were 31.83 and 106.11 μg L-1 and 59.16 and 197.22 μg L-1 for IC and TC, respectively. The evaluation of the performance of the water purification system indicated that an adequate procedure for cleaning of the storage tank is important to maintain TOC concentration about 100 μg L-1. TOC /IC analysis can be used as an indicator of the need for maintenance of the purification system. Some commercial packed WFI presented TOC above 500 μg L-1. The TOC monitoring during evaluation of the performance of purification systems for laboratory use coupled with storage tank indicated that they are suitable equipment for obtaining PW and WFI in radiopharmacies.
144

The role of medical representative in the Hong Kong pharmaceutical industry: research paper.

January 1978 (has links)
by Fung Hon Yue. / Thesis (M.B.A.)--Chinese University of Hong Kong, 1978. / Bibliography: leaf [70]
145

As conseqüências de culturas de alto desempenho para os profissionais de organizações do segmento químico e farmacêutico

Bayma, Lígia Helena Fürbringer 18 May 2011 (has links)
Made available in DSpace on 2016-04-25T20:20:13Z (GMT). No. of bitstreams: 1 Ligia Helena Furbringer Bayma.pdf: 424359 bytes, checksum: 16b586cc6c7319e538146e84382ae327 (MD5) Previous issue date: 2011-05-18 / The dissertation is about the Consequences of High performance targets for the company workers (employees), in companies that has it as basic premises, that let those premises very clear for anyone, through their attitudes, through their speeches, values and which are exposed everywhere, to be reached to every single person inside the company. These high performance values are also formal and frequently disseminated to all employees. To explain this subject, high performance culture, we will use as focal point for exemples, the pharmaceutical industry as well as employees interviewed to build a sample, which objectives are: To analyze the consequences of such high performance exigencies to employees in companies that has high performance aim, as overuse of pressure and its consequences for people; in their behavior , attitudes, analyzing the permissive behavior to achieve high performance results, where everything becomes possible and valid; and finally, how these consequences are seen (if loss of quality of life or an illness) and dealed as an individual limit and not a result of overuse of work limits, work processes. To conclude, we will be able to realize that as much as we still having a matrix that has this aims and therefore stimulates this kind of behavior for extreamly high results, we will still have these over stimulation for workers in the present time and also for the future generation, because this is part of the culture. The proposal of this research is to help companies to check and to begin to analyze high performance measures, that can be stablished to minimize such high performance impacts to the workers, and that through people they still can have high organizational results with better quality of life for the employees, and better than that, they will be able to develop healthy companies, which are made basically by people / A dissertação aqui apresentada trata das consequências das culturas de alto desempenho ou performance para as pessoas que estão dentro das organizações onde essas culturas são utilizadas como premissa básica. Essas organizações exprimem seu desejo de alto desempenho, por meio de suas atitudes, discursos presentes na descrição de seus valores, divulgados amplamente em todos os espaços de ampla circulação e de fácil visualização. Esses valores são ainda divulgados formalmente e com frequência a todos os seus funcionários. Para tratar desse assunto, teremos como ponto focal e como exemplo dessa cultura a indústria farmacêutica, assim como os respondentes de uma amostra qualitativa sistemática, que são os profissionais que nela trabalham ou trabalharam. Com isso, temos por objetivo: Analisar as consequências das exigências da cultura de alto desempenho para os profissionais que trabalham em organizações que as explicitam, evidenciando a pressão sofrida pelos indivíduos trabalhadores; o desconforto gerado por essa pressão; os comportamentos e atitudes de alto desempenho, fundamentados na permissividade na busca de resultados. Analisar também o modo como as consequências geradas para os indivíduos são tratadas: como limites individuais e não como um resultado do processo de trabalho. Concluiremos que, enquanto houver a gestão matriz incentivando a continuidade desses hábitos, eles continuarão presentes nas futuras gerações, e isso está inserido na cultura vigente. A proposta desta pesquisa é auxiliar as corporações com relação às medidas que podem ser tomadas para minimizar esses impactos na condução de seus profissionais. Tem-se também o intuito de que as organizações se tornem mais saudáveis, proporcionando aos seus funcionários melhor qualidade de vida e, consequentemente, de trabalho
146

As conseqüências de culturas de alto desempenho para os profissionais de organizações do segmento químico e farmacêutico

Bayma, Lígia Helena Fürbringer 18 May 2011 (has links)
Made available in DSpace on 2016-04-26T14:53:02Z (GMT). No. of bitstreams: 1 Ligia Helena Furbringer Bayma.pdf: 424359 bytes, checksum: 16b586cc6c7319e538146e84382ae327 (MD5) Previous issue date: 2011-05-18 / The dissertation is about the Consequences of High performance targets for the company workers (employees), in companies that has it as basic premises, that let those premises very clear for anyone, through their attitudes, through their speeches, values and which are exposed everywhere, to be reached to every single person inside the company. These high performance values are also formal and frequently disseminated to all employees. To explain this subject, high performance culture, we will use as focal point for exemples, the pharmaceutical industry as well as employees interviewed to build a sample, which objectives are: To analyze the consequences of such high performance exigencies to employees in companies that has high performance aim, as overuse of pressure and its consequences for people; in their behavior , attitudes, analyzing the permissive behavior to achieve high performance results, where everything becomes possible and valid; and finally, how these consequences are seen (if loss of quality of life or an illness) and dealed as an individual limit and not a result of overuse of work limits, work processes. To conclude, we will be able to realize that as much as we still having a matrix that has this aims and therefore stimulates this kind of behavior for extreamly high results, we will still have these over stimulation for workers in the present time and also for the future generation, because this is part of the culture. The proposal of this research is to help companies to check and to begin to analyze high performance measures, that can be stablished to minimize such high performance impacts to the workers, and that through people they still can have high organizational results with better quality of life for the employees, and better than that, they will be able to develop healthy companies, which are made basically by people / A dissertação aqui apresentada trata das consequências das culturas de alto desempenho ou performance para as pessoas que estão dentro das organizações onde essas culturas são utilizadas como premissa básica. Essas organizações exprimem seu desejo de alto desempenho, por meio de suas atitudes, discursos presentes na descrição de seus valores, divulgados amplamente em todos os espaços de ampla circulação e de fácil visualização. Esses valores são ainda divulgados formalmente e com frequência a todos os seus funcionários. Para tratar desse assunto, teremos como ponto focal e como exemplo dessa cultura a indústria farmacêutica, assim como os respondentes de uma amostra qualitativa sistemática, que são os profissionais que nela trabalham ou trabalharam. Com isso, temos por objetivo: Analisar as consequências das exigências da cultura de alto desempenho para os profissionais que trabalham em organizações que as explicitam, evidenciando a pressão sofrida pelos indivíduos trabalhadores; o desconforto gerado por essa pressão; os comportamentos e atitudes de alto desempenho, fundamentados na permissividade na busca de resultados. Analisar também o modo como as consequências geradas para os indivíduos são tratadas: como limites individuais e não como um resultado do processo de trabalho. Concluiremos que, enquanto houver a gestão matriz incentivando a continuidade desses hábitos, eles continuarão presentes nas futuras gerações, e isso está inserido na cultura vigente. A proposta desta pesquisa é auxiliar as corporações com relação às medidas que podem ser tomadas para minimizar esses impactos na condução de seus profissionais. Tem-se também o intuito de que as organizações se tornem mais saudáveis, proporcionando aos seus funcionários melhor qualidade de vida e, consequentemente, de trabalho
147

[en] THE GENERIC DRUGS LAUNCH AND THEIR IMPACT ON THE COMPETITIVE STRATEGIES OF THE BRAZILIAN PHARMACEUTICAL INDUSTRY / [pt] O ADVENTO DOS GENÉRICOS E SEU IMPACTO NAS ESTRATÉGIAS COMPETITIVAS DA INDÚSTRIA FARMACÊUTICA BRASILEIRA

FELIPE DAVID COHEN 15 April 2004 (has links)
[pt] O propósito deste estudo é analisar o advento dos genéricos e verificar seu impacto nas estratégias competitivas implementadas por empresas da indústria farmacêutica brasileira. Este trabalho adota como base o estudo de Michael Porter sobre tipologias, identificando as estratégias relevantes e os grupamentos existentes nesse segmento industrial, buscando também relacionar o posicionamento estratégico assumido pelos laboratórios ao desempenho observado. O método de análise constitui-se do levantamento de uma base de dados obtida a partir de relatórios de consultorias especializadas, da identificação de indicadores estratégicos e de desempenho, bem como da implementação de procedimentos estatísticos. Busca-se ainda relacionar os posicionamentos e desempenhos identificados entre os anos de 1999 e 2002 aos resultados obtidos no estudo envolvendo o período imediatamente anterior ao advento dos genéricos, isto é, ao período compreendido entre os anos de 1995 e 1998, permitindo-se assim a elaboração de uma análise longitudinal da indústria. Os resultados obtidos sugerem um forte deslocamento no sentido de adoção de custos como arma estratégica, bem como demonstram uma perda de foco estratégico por parte dos laboratórios voltados à diferenciação. Por fim, o estudo também identifica indícios de queda na rentabilidade total da indústria. / [en] The aim of this study is to analyze the launching of generic drugs and verify their impact on competitive strategies implemented by Brazilian pharmaceutical companies during the period of 1999 to 2002. This research is based on Michael Porter´s studies on strategic typologies, identifying the relevant strategies and the existing groups in this industrial sector. The study also relates the strategic positioning of the pharmaceutical companies to the achieved performance. The methodology adopted is based on the analysis of collected database from reports of specialized consulting companies, the survey of strategy and performance indicators, as well as the implementation of statistical procedures. Furthermore, the relation of positioning and performance identified in this study to the results obtained in a previous one involving the pharmaceutical industry during the period immediately before the generic drugs launching, that is, the period between the years 1995 and 1998, is also investigated, thus allowing a longitudinal analysis of the Brazilian pharmaceutical industry. The results suggest a movement to adoption of cost as strategy, as well as demonstrate a loss of strategic focus of the pharmaceutical companies that are oriented to differentiation. Finally, the study also identifies a reduction yield trend of the pharmaceutical industry.
148

HOLMES: A Hybrid Ontology-Learning Materials Engineering System

Remolona, Miguel Francisco Miravite January 2018 (has links)
Designing and discovering novel materials is challenging problem in many domains such as fuel additives, composites, pharmaceuticals, and so on. At the core of all this are models that capture how the different domain-specific data, information, and knowledge regarding the structures and properties of the materials are related to one another. This dissertation explores the difficult task of developing an artificial intelligence-based knowledge modeling environment, called Hybrid Ontology-Learning Materials Engineering System (HOLMES) that can assist humans in populating a materials science and engineering ontology through automatic information extraction from journal article abstracts. While what we propose may be adapted for a generic materials engineering application, our focus in this thesis is on the needs of the pharmaceutical industry. We develop the Columbia Ontology for Pharmaceutical Engineering (COPE), which is a modification of the Purdue Ontology for Pharmaceutical Engineering. COPE serves as the basis for HOLMES. The HOLMES framework starts with journal articles that are in the Portable Document Format (PDF) and ends with the assignment of the entries in the journal articles into ontologies. While this might seem to be a simple task of information extraction, to fully extract the information such that the ontology is filled as completely and correctly as possible is not easy when considering a fully developed ontology. In the development of the information extraction tasks, we note that there are new problems that have not arisen in previous information extraction work in the literature. The first is the necessity to extract auxiliary information in the form of concepts such as actions, ideas, problem specifications, properties, etc. The second problem is in the existence of multiple labels for a single token due to the existence of the aforementioned concepts. These two problems are the focus of this dissertation. In this work, the HOLMES framework is presented as a whole, describing our successful progress as well as unsolved problems, which might help future research on this topic. The ontology is then presented to help in the identification of the relevant information that needs to be retrieved. The annotations are next developed to create the data sets necessary for the machine learning algorithms to perform. Then, the current level of information extraction for these concepts is explored and expanded. This is done through the introduction of entity feature sets that are based on previously extracted entities from the entity recognition task. And finally, the new task of handling multiple labels for tagging a single entity is also explored by the use of multiple-label algorithms used primarily in image processing.
149

Robust Process Monitoring for Continuous Pharmaceutical Manufacturing

Mariana Moreno (5930069) 03 January 2019 (has links)
<p>Robust process monitoring in real-time is a challenge for Continuous Pharmaceutical Manufacturing. Sensors and models have been developed to help to make process monitoring more robust, but they still need to be integrated in real-time to produce reliable estimates of the true state of the process. Dealing with random and gross errors in the process measurements in a systematic way is a potential solution. In this work, we present such a systematic framework, which for a given sensor network and measurement uncertainties will predict the most likely state of the process. As a result, real-time process decisions, whether for process control, exceptional events management or process optimization can be based on the most reliable estimate of the process state.</p><p><br></p><p></p><p>Data reconciliation (DR) and gross error detection (GED) have been developed to accomplish robust process monitoring. DR and GED mitigate the effects of random measurement errors and non-random sensor malfunctions. This methodology has been used for decades in other industries (i.e., Oil and Gas), but it has yet to be applied to the Pharmaceutical Industry. Steady-state data reconciliation (SSDR) is the simplest forms of DR but offers the benefits of short computational times. However, it requires the sensor network to be redundant (i.e., the number of measurements has to be greater than the degrees of freedom).</p><p><br></p><p>In this dissertation, the SSDR framework is defined and implemented it in two different continuous tableting lines: direct compression and dry granulation. The results for two pilot plant scales via continuous direct compression tableting line are reported in this work. The two pilot plants had different equipment and sensor configurations. The results for the dry granulation continuous tableting line studies were also reported on a pilot-plant scale in an end-to-end operation. New measurements for the dry granulation continuous tableting line are also proposed in this work.</p><p><br></p><p></p><p>A comparison is made for the model-based DR approach (SSDR-M) and the purely data-driven approach (SSDR-D) based on the use of principal component constructions. If the process is linear or mildly nonlinear, SSDR-M and SSDR-D give comparable results for the variables estimation and GED. The reconciled measurement values generate using SSDR-M satisfy the model equations and can be used together with the model to estimate unmeasured variables. However, in the presence of nonlinearities, the SSDR-M and SSDR-D will differ. SSDR successfully estimates the real state of the process in the presence of gross errors, as long as steady-state is maintained and the redundancy requirement is met. Gross errors are also detected whether using SSDR-M or SSDR-D. </p><p><br></p>
150

The making of liqui-pellet and liqui-tablet, the next generation oral dosage form

Lam, Matthew January 2019 (has links)
No description available.

Page generated in 0.0754 seconds